Skip to main content
Top
Published in: Clinical Phytoscience 1/2017

Open Access 01-01-2017 | Original contribution

Senna alata leaf extract restores insulin sensitivity in high-fat diet-induced obese mice

Authors: Jarinyaporn Naowaboot, Pritsana Piyabhan

Published in: Clinical Phytoscience | Issue 1/2017

Login to get access

Abstract

Background

Senna alata (S. alata) has numerous pharmacological activities including anti-lipogenic effect in high-fat diet (HFD)-induced obese mice. The present study investigated the effect of Senna alata (S. alata) leaf extracts on the regulation of abnormal glucose metabolism in HFD-induced obese mice.

Methods

Male ICR mice were induced to become obese by being fed a HFD (45 kcal% lard fat) for 12 weeks. During the last 6 weeks of diet feeding, the obese mice were treated with the water extract of S. alata leaf at 250 and 500 mg/kg/day. After 6 weeks of treatment, blood was collected for measuring biochemical parameters. The liver, epididymal fat and skeletal muscle tissues were excised and kept for determining histology and western blot analysis.

Results

Treatment with S. alata (250 and 500 mg/kg) significantly reduced hyperglycemia, hyperinsulinemia, and hyperleptinemia. The glucose intolerance was improved by S. alata. The elevated monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-α (TNF-α) levels in obese mice were reduced in S. alata treatment. The level of serum adiponectin was increased in obese mice treated with S. alata (250 and 500 mg/kg). The epididymal fat weight was reduced in S. alata treatment. The enlarged adipocyte size was smaller in obese mice treated with S. alata. In comparison with the obese control mice, the mice treated with S. alata showed a significant reduction of liver glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK) proteins. Moreover, S. alata up-regulated the liver and muscle adenosine monophosphate-activated protein kinase phosphorylation (pAMPK) and muscle glucose transporter 4 (GLUT4).

Conclusions

The results indicate that the restoration of impaired glucose metabolism of S. alata may be associated with reduced hepatic gluconeogenesis and increased glucose uptake via AMPK activation.
Literature
1.
go back to reference Valera A, Pujol A, Pelegrin M, Bosch F. Transgenic mice overexpressing phosphoenolpyruvate carboxykinase develop non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A. 1994;91:9151–4.CrossRefPubMedPubMedCentral Valera A, Pujol A, Pelegrin M, Bosch F. Transgenic mice overexpressing phosphoenolpyruvate carboxykinase develop non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A. 1994;91:9151–4.CrossRefPubMedPubMedCentral
2.
go back to reference Trinh KY, O’Doherty RM, Anderson P, Lange AJ, Newgard CB. Perturbation of fuel homeostasis caused by overexpression of the glucose-6-phosphatase catalytic subunit in liver of normal rats. J Biol Chem. 1998;273:31615–20.CrossRefPubMed Trinh KY, O’Doherty RM, Anderson P, Lange AJ, Newgard CB. Perturbation of fuel homeostasis caused by overexpression of the glucose-6-phosphatase catalytic subunit in liver of normal rats. J Biol Chem. 1998;273:31615–20.CrossRefPubMed
3.
go back to reference Watson RT, Pessin JE. Intracellular organization of insulin signaling and GLUT4 translocation. Recent Prog Horm Res. 2001;56:175–93.CrossRefPubMed Watson RT, Pessin JE. Intracellular organization of insulin signaling and GLUT4 translocation. Recent Prog Horm Res. 2001;56:175–93.CrossRefPubMed
4.
go back to reference Takikawa M, Inoue S, Horio F, Tsuda T. Dietary anthocyanin-rich bilberry extract ameliorates hyperglycemia and insulin sensitivity via activation of AMP-activated protein kinase in diabetic mice. J Nutr. 2010;140:527–33.CrossRefPubMed Takikawa M, Inoue S, Horio F, Tsuda T. Dietary anthocyanin-rich bilberry extract ameliorates hyperglycemia and insulin sensitivity via activation of AMP-activated protein kinase in diabetic mice. J Nutr. 2010;140:527–33.CrossRefPubMed
5.
go back to reference Foretz M, Ancellin N, Andreelli F, Saintillan Y, Grondin P, Kahn A, et al. Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes. 2005;54:1331–9.CrossRefPubMed Foretz M, Ancellin N, Andreelli F, Saintillan Y, Grondin P, Kahn A, et al. Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes. 2005;54:1331–9.CrossRefPubMed
6.
go back to reference Fujii N, Ho RC, Manabe Y, Jessen N, Toyoda T, Holland WL, et al. Ablation of AMP-activated protein kinase alpha2 activity exacerbates insulin resistance induced by high-fat feeding of mice. Diabetes. 2008;57:2958–66.CrossRefPubMedPubMedCentral Fujii N, Ho RC, Manabe Y, Jessen N, Toyoda T, Holland WL, et al. Ablation of AMP-activated protein kinase alpha2 activity exacerbates insulin resistance induced by high-fat feeding of mice. Diabetes. 2008;57:2958–66.CrossRefPubMedPubMedCentral
7.
go back to reference Srivastava RA, Pinkosky SL, Filippov S, Hanselman JC, Cramer CT, Newton RS. AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases. J Lipid Res. 2012;53:2490–514.CrossRefPubMedPubMedCentral Srivastava RA, Pinkosky SL, Filippov S, Hanselman JC, Cramer CT, Newton RS. AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases. J Lipid Res. 2012;53:2490–514.CrossRefPubMedPubMedCentral
8.
go back to reference Zhang BB, Zhou G, Li C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab. 2009;9:407–16.CrossRefPubMed Zhang BB, Zhou G, Li C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab. 2009;9:407–16.CrossRefPubMed
9.
go back to reference Hwang JT, Kwon DY, Yoon SH. AMP-activated protein kinase: a potential target for the diseases prevention by natural occurring polyphenols. N Biotechnol. 2009;26:17–22.CrossRefPubMed Hwang JT, Kwon DY, Yoon SH. AMP-activated protein kinase: a potential target for the diseases prevention by natural occurring polyphenols. N Biotechnol. 2009;26:17–22.CrossRefPubMed
10.
go back to reference Olarte EI, Herrera AA, Villasenor IM, Jacinto SD. In vitro antitumor properties of an isolate from leaves of Cassia alata L. Asian Pac J Cancer Prev. 2013;14:3191–6.CrossRefPubMed Olarte EI, Herrera AA, Villasenor IM, Jacinto SD. In vitro antitumor properties of an isolate from leaves of Cassia alata L. Asian Pac J Cancer Prev. 2013;14:3191–6.CrossRefPubMed
11.
go back to reference Kundu S, Roy S, Lyndem LM. Cassia alata L: potential role as anthelmintic agent against Hymenolepis diminuta. Parasitol Res. 2012;111:1187–92.CrossRefPubMed Kundu S, Roy S, Lyndem LM. Cassia alata L: potential role as anthelmintic agent against Hymenolepis diminuta. Parasitol Res. 2012;111:1187–92.CrossRefPubMed
12.
go back to reference Otto RB, Ameso S, Onegi B. Assessment of antibacterial activity of crude leaf and root extracts of Cassia alata against Neisseria gonorrhea. Afr Health Sci. 2014;14:840–8.CrossRefPubMedPubMedCentral Otto RB, Ameso S, Onegi B. Assessment of antibacterial activity of crude leaf and root extracts of Cassia alata against Neisseria gonorrhea. Afr Health Sci. 2014;14:840–8.CrossRefPubMedPubMedCentral
13.
go back to reference Sagnia B, Fedeli D, Casetti R, Montesano C, Falcioni G, Colizzi V. Antioxidant and anti-inflammatory activities of extracts from Cassia alata, Eleusine indica, Eremomastax speciosa, Carica papaya and Polyscias fulva medicinal plants collected in Cameroon. PloS One. 2014;9:e103999.CrossRefPubMedPubMedCentral Sagnia B, Fedeli D, Casetti R, Montesano C, Falcioni G, Colizzi V. Antioxidant and anti-inflammatory activities of extracts from Cassia alata, Eleusine indica, Eremomastax speciosa, Carica papaya and Polyscias fulva medicinal plants collected in Cameroon. PloS One. 2014;9:e103999.CrossRefPubMedPubMedCentral
14.
go back to reference Varghese GK, Bose LV, Habtemariam S. Antidiabetic components of Cassia alata leaves: identification through alpha-glucosidase inhibition studies. Pharm Biol. 2013;51:345–9.CrossRefPubMed Varghese GK, Bose LV, Habtemariam S. Antidiabetic components of Cassia alata leaves: identification through alpha-glucosidase inhibition studies. Pharm Biol. 2013;51:345–9.CrossRefPubMed
15.
go back to reference Naowaboot J, Wannasiri S. Anti-lipogenic effect of Senna alata leaf extract in high-fat diet-induced obese mice. Asian Pac J Trop Biomed. 2016;6:232–8.CrossRef Naowaboot J, Wannasiri S. Anti-lipogenic effect of Senna alata leaf extract in high-fat diet-induced obese mice. Asian Pac J Trop Biomed. 2016;6:232–8.CrossRef
16.
go back to reference Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology. 2010;52:774–88.CrossRefPubMed Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology. 2010;52:774–88.CrossRefPubMed
17.
go back to reference Cao R, Cronk ZX, Zha W, Sun L, Wang X, Fang Y, et al. Bile acids regulate hepatic gluconeogenic genes and farnesoid X receptor via G(alpha)i-protein-coupled receptors and the AKT pathway. J Lipid Res. 2010;51:2234–44.CrossRefPubMedPubMedCentral Cao R, Cronk ZX, Zha W, Sun L, Wang X, Fang Y, et al. Bile acids regulate hepatic gluconeogenic genes and farnesoid X receptor via G(alpha)i-protein-coupled receptors and the AKT pathway. J Lipid Res. 2010;51:2234–44.CrossRefPubMedPubMedCentral
18.
go back to reference Kabir M, Catalano KJ, Ananthnarayan S, Kim SP, Van Citters GW, Dea MK, et al. Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance. Am J Physiol Endocrinol Metab. 2005;288:E454–61.CrossRefPubMed Kabir M, Catalano KJ, Ananthnarayan S, Kim SP, Van Citters GW, Dea MK, et al. Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance. Am J Physiol Endocrinol Metab. 2005;288:E454–61.CrossRefPubMed
19.
go back to reference Foretz M, Taleux N, Guigas B, Horman S, Beauloye C, Andreelli F, et al. [Regulation of energy metabolism by AMPK: a novel therapeutic approach for the treatment of metabolic and cardiovascular diseases]. Med Sci (Paris). 2006;22:381–8.CrossRef Foretz M, Taleux N, Guigas B, Horman S, Beauloye C, Andreelli F, et al. [Regulation of energy metabolism by AMPK: a novel therapeutic approach for the treatment of metabolic and cardiovascular diseases]. Med Sci (Paris). 2006;22:381–8.CrossRef
20.
go back to reference Viollet B, Lantier L, Devin-Leclerc J, Hebrard S, Amouyal C, Mounier R, et al. Targeting the AMPK pathway for the treatment of Type 2 diabetes. Front Biosci (Landmark Ed). 2009;14:3380–400.CrossRef Viollet B, Lantier L, Devin-Leclerc J, Hebrard S, Amouyal C, Mounier R, et al. Targeting the AMPK pathway for the treatment of Type 2 diabetes. Front Biosci (Landmark Ed). 2009;14:3380–400.CrossRef
21.
go back to reference Andreelli F, Foretz M, Knauf C, Cani PD, Perrin C, Iglesias MA, et al. Liver adenosine monophosphate-activated kinase-alpha2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin. Endocrinology. 2006;147:2432–41.CrossRefPubMed Andreelli F, Foretz M, Knauf C, Cani PD, Perrin C, Iglesias MA, et al. Liver adenosine monophosphate-activated kinase-alpha2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin. Endocrinology. 2006;147:2432–41.CrossRefPubMed
22.
go back to reference Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215–22.CrossRefPubMed Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215–22.CrossRefPubMed
24.
go back to reference Ceddia RB, Somwar R, Maida A, Fang X, Bikopoulos G, Sweeney G. Globular adiponectin increases GLUT4 translocation and glucose uptake but reduces glycogen synthesis in rat skeletal muscle cells. Diabetologia. 2005;48:132–9.CrossRefPubMed Ceddia RB, Somwar R, Maida A, Fang X, Bikopoulos G, Sweeney G. Globular adiponectin increases GLUT4 translocation and glucose uptake but reduces glycogen synthesis in rat skeletal muscle cells. Diabetologia. 2005;48:132–9.CrossRefPubMed
25.
go back to reference Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res. 2007;100:328–41.CrossRefPubMed Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res. 2007;100:328–41.CrossRefPubMed
26.
go back to reference Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116:1784–92.CrossRefPubMedPubMedCentral Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116:1784–92.CrossRefPubMedPubMedCentral
27.
go back to reference Villena JA, Viollet B, Andreelli F, Kahn A, Vaulont S, Sul HS. Induced adiposity and adipocyte hypertrophy in mice lacking the AMP-activated protein kinase-alpha2 subunit. Diabetes. 2004;53:2242–9.CrossRefPubMed Villena JA, Viollet B, Andreelli F, Kahn A, Vaulont S, Sul HS. Induced adiposity and adipocyte hypertrophy in mice lacking the AMP-activated protein kinase-alpha2 subunit. Diabetes. 2004;53:2242–9.CrossRefPubMed
28.
go back to reference Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia. 2003;46:1594–603.CrossRefPubMed Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia. 2003;46:1594–603.CrossRefPubMed
29.
30.
go back to reference Jeong HW, Hsu KC, Lee JW, Ham M, Huh JY, Shin HJ, et al. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am J Physiol Endocrinol Metab. 2009;296:E955–64.CrossRefPubMed Jeong HW, Hsu KC, Lee JW, Ham M, Huh JY, Shin HJ, et al. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am J Physiol Endocrinol Metab. 2009;296:E955–64.CrossRefPubMed
31.
go back to reference Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259:87–91.CrossRefPubMed Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259:87–91.CrossRefPubMed
32.
go back to reference Ahn J, Lee H, Kim S, Park J, Ha T. The anti-obesity effect of quercetin is mediated by the AMPK and MAPK signaling pathways. Biochem Biophys Res Commun. 2008;373:545–9.CrossRefPubMed Ahn J, Lee H, Kim S, Park J, Ha T. The anti-obesity effect of quercetin is mediated by the AMPK and MAPK signaling pathways. Biochem Biophys Res Commun. 2008;373:545–9.CrossRefPubMed
33.
go back to reference Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5:493–506.CrossRefPubMed Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5:493–506.CrossRefPubMed
34.
go back to reference Kim WS, Lee YS, Cha SH, Jeong HW, Choe SS, Lee MR, et al. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am J Physiol Endocrinol Metab. 2009;296:E812–9.CrossRefPubMed Kim WS, Lee YS, Cha SH, Jeong HW, Choe SS, Lee MR, et al. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am J Physiol Endocrinol Metab. 2009;296:E812–9.CrossRefPubMed
35.
go back to reference Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006;55:2256–64.CrossRefPubMed Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006;55:2256–64.CrossRefPubMed
Metadata
Title
Senna alata leaf extract restores insulin sensitivity in high-fat diet-induced obese mice
Authors
Jarinyaporn Naowaboot
Pritsana Piyabhan
Publication date
01-01-2017
Publisher
Springer Berlin Heidelberg
Published in
Clinical Phytoscience / Issue 1/2017
Electronic ISSN: 2199-1197
DOI
https://doi.org/10.1186/s40816-016-0032-5

Other articles of this Issue 1/2017

Clinical Phytoscience 1/2017 Go to the issue